Category: biotech

.Chinese insulin manufacturer Gan &amp Lee Pharmaceuticals is actually wading into the weight problems planet with an injectable GLP-1 agonist that beat Novo Nordisk’s Ozempic

.China-based Minghui Drug has actually connected its own thyroid eye ailment treatment to a decline in eye protruding in a little period 1b/2 medical trial.The

.Charles Baum, M.D., Ph.D., who managed Mirati Rehabs’ $ 5.8 billion sale to Bristol Myers Squibb in 2015, is taking the reins of young biotech

.It’s hard to muscular tissue in on an area as affordable as immunology, but Celldex Therapies strongly believes that its most current period 2 gain

.Invite to recently’s Chutes &amp Ladders, our roundup of significant leadership hirings, firings and retirings all over the market. Feel free to send out the

.Cassava Sciences has consented to pay out $40 million to address an inspection into insurance claims it created deceptive declarations about stage 2b information on

.Gritstone biography has actually brought in bankers to discover “prospective value-maximizing techniques” after its period 2 colon cancer vaccine records fell short of the wild

.Capricor Therapeutics is taking a triumph lap for their period 2 Duchenne muscle dystrophy (DMD) trial. At 3 years, the San Diego-based company’s cell treatment

.Having actually scooped up the U.S. rights to Capricor Therapies’ late-stage Duchenne muscle dystrophy (DMD) treatment, Japan’s Nippon Shinyaku has actually approved $35 million in

.RNA biotech CAMP4 Rehabs has marked out think about a $67 thousand IPO, with inflammation-focused Upstream Bio fixing its own aspirations at $182 million.While Upstream